Now Available:
Download the podcasts of MSK video reports from AAOS 2008

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment. MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.

Bones: LRP5 Gene Variants Linked to Fractures, Lower BMD
Common LRP5 gene variants are associated with an increased risk for fractures and lower levels of bone mineral density (BMD) in the spine and hip across different white populations...

Autoimmunity: Two-Pronged Strategy for Treating PAH in Lupus or Mixed Connective Tissue Disease
Lupus or MCTD patients with pulmonary arterial hypertension (PAH) should be treated with cyclophosphamide and glucocorticoids, with added pulmonary vasodilators in more severe cases...

Consumer News: Pain Relief for Osteoporosis Patients With Fractures
Vertobroplasty provides significant pain relief for osteoporosis patients with spinal fractures...

New from PubMed: Sickle Cell Bone Disease: Response to Vitamin D and Calcium
Patients with sickle cell disease should be screened for vitamin D deficiency and low bone mineral density...

BioPharm Business: Centocor, Schering-Plough Submit Marketing Authorization Application Requesting EU Approval of Golimumab to Treat RA, PsA, AS
Centocor, Inc and Schering-Plough Corp are seeking EU approval of golimumab, which targets and neutralizes both the soluble and membrane-bound forms of TNFα, to treat RA, PsA, and AS...

BioPharm Business: Merrimack Pharmaceuticals Completes Enrollment in a Phase II Study of MM-093, Recombinant AFP, in Patients With RA
Merrimack Pharmaceuticals, Inc's phase II trial to evaluate the safety and efficacy of MM-093, a nonglycosylated, recombinant version of human alpha-fetoprotein (AFP) in patients suffering from rheumatoid arthritis (RA) has completed enrollment...

To remove your e-mail address from our mailing list, please reply to this e-mail with "unsubscribe" in the subject line. For questions and comments regarding this newsletter please contact .